Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
– Calls to unite global communities affected by rare diseases – – Albireo supports increasing education and advances in research for rare cholestatic liver diseases – BOSTON, Feb. 26, 2021 (GLOBE...
-
– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch – – Announces odevixibat co-promotion agreement with Travere, a leading rare disease company – – ASSERT global pivotal...
-
BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced...
-
BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
-
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of...
-
– Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU launch, with focus on market access – – Expansion opportunity...
-
- Company receives FDA Priority Review with PDUFA date set for July 20, 2021 - - Submission data for PFIC types 1, 2, 3, supporting once-daily use across a wide range of patients - - FDA has granted...
-
BOSTON, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today joins the Alagille community...
-
BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of...
-
BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a...